Bone Neoplasms

Publication Title: 
Clinical Orthopaedics and Related Research

BACKGROUND: Orthopaedic oncologists often must address leg-length discrepancy after resection of tumors in growing patients with osteosarcoma. There are various alternatives to address this problem. We describe a three-stage procedure: (1) temporary arthrodesis, (2) lengthening by Ilizarov apparatus, and (3) tumor prosthesis.

Author(s): 
Kong, Chang-Bae
Lee, Soo-Yong
Jeon, Dae-Geun
Publication Title: 
International Journal of Oncology

Metastatic chondrosarcoma of mesenchymal origin is the second most common bone malignancy and does not respond either to chemotherapy or radiation; therefore, the search for new therapies is relevant and urgent. We described recently that tumor growth inhibiting cytostatic proline-rich polypeptide 1, (PRP-1) significantly upregulated tumor suppressor miRNAs, downregulated onco-miRNAs in human chondrosarcoma JJ012 cell line, compared to chondrocytes culture.

Author(s): 
Galoian, Karina
Qureshi, Amir
D'Ippolito, Gianluca
Schiller, Paul C.
Molinari, Marco
Johnstone, Andrea L.
Brothers, Shaun P.
Paz, Ana C.
Temple, H. T.
Publication Title: 
Wiener Medizinische Wochenschrift (1946)

Pain--which can have a variety of causes--constitutes a severe problem for patients in need of palliative care, because this pain usually dramatically impairs their quality of life. Thus, the more advanced a terminal illness has become, the more hospital staff should focus on holistic treatment, encompassing body, mind and soul of the patient. Apart from conventional medication-based pain therapy, there is also a variety of non-medicinal treatments for pain.

Author(s): 
Peintinger, Christa
Hartmann, Wolfgang
Publication Title: 
Health Psychology: Official Journal of the Division of Health Psychology, American Psychological Association

OBJECTIVE: To examine whether a group intervention including hypnosis can reduce cancer pain and trait hypnotizability would moderate these effects. DESIGN: This randomized clinical trial examined the effects of group therapy with hypnosis (supportive-expressive group therapy) plus education compared to an education-only control condition on pain over 12 months among 124 women with metastatic breast cancer. MAIN OUTCOME MEASURES: Pain and suffering, frequency of pain, and degree of constant pain were assessed at baseline and 4-month intervals.

Author(s): 
Butler, Lisa D.
Koopman, Cheryl
Neri, Eric
Giese-Davis, Janine
Palesh, Oxana
Thorne-Yocam, Krista A.
Dimiceli, Sue
Chen, Xin-Hua
Fobair, Patricia
Kraemer, Helena C.
Spiegel, David
Publication Title: 
Molecular cancer research: MCR

Most patients with cancer die not because of the tumor in the primary site, but because it has spread to other sites. Common tumors, such as breast, multiple myeloma, and prostate tumors, frequently metastasize to the bone. It is now well recognized that osteoclasts are responsible for the osteolysis observed in bone metastases of the tumor.

Author(s): 
Reuter, Simone
Prasad, Sahdeo
Phromnoi, Kanokkarn
Kannappan, Ramaswamy
Yadav, Vivek R.
Aggarwal, Bharat B.
Publication Title: 
Molecular Cancer Therapeutics

Bone loss is one of the major complications of advanced cancers such as breast cancer, prostate cancer, and multiple myeloma; agents that can suppress this bone loss have therapeutic potential. Extensive research within the last decade has revealed that RANKL, a member of the tumor necrosis factor superfamily, plays a major role in cancer-associated bone resorption and thus is a therapeutic target.

Author(s): 
Sung, Bokyung
Oyajobi, Babatunde
Aggarwal, Bharat B.
Publication Title: 
International Journal of Oncology

We previously established a bioassay method to screen for compounds that activate the promoter activity of p21(WAF1/CIP1), a potent inhibitor of cyclin-dependent kinases, in a p53-independent manner. As an activator of p21(WAF1/CIP1) promoter activity, we isolated cryptolepine (CLP: 5-methyl indolo (2,3b)-quiniine), an indoloquinoline alkaloid, from the traditional Ayurvedic medicinal plant Sida cordifolia. We show here that CLP induces the expression of p21(WAF1/CIP1) with growth arrest in p53-mutated human osteosarcoma MG63 cells.

Author(s): 
Matsui, Taka-aki
Sowa, Yoshihiro
Murata, Hiroaki
Takagi, Koichi
Nakanishi, Ryoko
Aoki, Shunji
Yoshikawa, Masayuki
Kobayashi, Motomasa
Sakabe, Tomoya
Kubo, Toshikazu
Sakai, Toshiyuki
Publication Title: 
Molecular cancer research: MCR

Most patients with cancer die not because of the tumor in the primary site, but because it has spread to other sites. Common tumors, such as breast, multiple myeloma, and prostate tumors, frequently metastasize to the bone. It is now well recognized that osteoclasts are responsible for the osteolysis observed in bone metastases of the tumor.

Author(s): 
Reuter, Simone
Prasad, Sahdeo
Phromnoi, Kanokkarn
Kannappan, Ramaswamy
Yadav, Vivek R.
Aggarwal, Bharat B.
Publication Title: 
Molecular Cancer Therapeutics

Bone loss is one of the major complications of advanced cancers such as breast cancer, prostate cancer, and multiple myeloma; agents that can suppress this bone loss have therapeutic potential. Extensive research within the last decade has revealed that RANKL, a member of the tumor necrosis factor superfamily, plays a major role in cancer-associated bone resorption and thus is a therapeutic target.

Author(s): 
Sung, Bokyung
Oyajobi, Babatunde
Aggarwal, Bharat B.
Publication Title: 
European Journal of Pain (London, England)

Cancer pain impairs the quality of life of cancer patients, but opioid intervention can cause significant side effects that further decrease quality of life. Although electroacupuncture (EA) has been used to treat cancer pain, its mechanisms are largely unknown. To examine its effects and underlying mechanisms on cancer pain, we injected AT-3.1 prostate cancer cells into the tibia to induce bone cancer in the male Copenhagen rat.

Author(s): 
Zhang, Rui-Xin
Li, Aihui
Liu, Bing
Wang, Linbo
Xin, Jiajia
Ren, Ke
Qiao, Jian-Tian
Berman, Brian M.
Lao, Lixing

Pages

Subscribe to RSS - Bone Neoplasms